Research progress of intralesional injection for advanced skin melanoma
TANG Bixia
CUI Chuanliang
GUO Jun
Abstract：Intralesional injection is an anti?tumor therapy in which the injected agents shrink the tumor directly and stimulate a systemic immune response to kill non?injected tumors( namely bystander effect) . Talimogene laherparepvec, an intralesional injection agent, was approved by U.S. Food and Drug Administration on October, 2015 for the local treatment of unresectable cutaneous, subcu?taneous and nodal lesions in patients with melanoma recurrent after initial surgery, inspiring more attention to this treatment method. In the current review, we summarize a series of intralesional injection agents(including cytokines, plasmid, oncolytic virus, etc.) for mel?anoma and propose future study in this field.
Keywords：MelanomaIntralesional injectionImmunotherapy
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 556-559 )